New hope for advanced cervical cancer: drug combo trial launches
NCT ID NCT07392060
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether a combination of two drugs, WX390 and toripalimab, can help people with recurrent or metastatic cervical cancer that has not responded to platinum-based chemotherapy. About 440 participants will be randomly assigned to receive either the new combination or standard chemotherapy. The main goal is to see if the new combination improves overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- WX390 and toripalimab (a combination of an experimental oral drug and an immunotherapy drug)
- What this could lead to
- If successful, this could provide a new treatment option for people with advanced cervical cancer that has stopped responding to standard chemotherapy.
- What could go wrong
- This is an early-stage Phase 3 trial, so the combination may not prove more effective than existing treatments. Side effects from the drugs could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.